• Miravitlles M, Calle M, Molina J, Almagro P, Gómez JT, Trigueros JA, Sánchez-Angarita E, Cosío BG, Casanova C, López-Campos JL, Riesco JA, Simonet P, Rigau D, Iskakova A, Pastor Sanz M, Sobradillo P, Alcázar-Navarrete B, Garin N, Soler-Cataluña JJ.
Update 2025 of the Spanish COPD Guidelines (GesEPOC): Pharmacological Treatment of Stable COPD
Arch Bronconeumol 2025;61(12):766-782
DOI: 10.1016/j.arbres.2025.10.008
IF: 9.2
RESEARCH GROUPS
Pneumology
66
Number of publications
77.27
%
% Q1
50.00
%
% D1
33.33
%
% Leadership
54.55
%
% Female Leadership
3.03
CROWN (2021-2025)
23.91
%
HCP10% (2021-2025)
72.73
%
% Open access
53.03
%
% International Collaboration
26
Highly cited papers / HCP 1% (2021-2025)
3
Publications in high-IF journals with high Altmetric scores
21
Number of Ongoing Projectes (total)
5
International ongoing projects
19
Number of New projects (total)
2
International new projects
63
Number of Active clinical Trials
11
Number of New Clinical Trials
8
Number of Theses
In 2025, our group led translational research in respiratory medicine, integrating mechanistic discoveries, multi-omics, and innovation into clinical practice. We ranked among the top five groups within CIBERES (Instituto de Salud Carlos III) and maintained active roles in ERN, XARTEC, XUEC, and as a CSUR-accredited national reference center. Our research addressed major respiratory diseases, including environmental conditions, severe asthma, lung transplantation, COPD, interstitial lung diseases, pulmonary hypertension, sleep disorders, respiratory infections, and post-COVID sequelae. We contributed to major European consortia (E-PHOCAS, ECRAID-Base) and advanced key priorities: early diagnosis and precision medicine through biomarkers and multi-omics; digital health via AI tools such as mScreenSleep; sustainable healthcare through projects like EXIMIOUS, EXPOSIM, and GreenSelfO2; and innovation via public–private collaborations supporting personalized therapies.
CORE/MISSIONS
- Environmental & Public Health
- Innovative & Advanced Therapies
- Rare Diseases
- Transplant & Immunomodulation
PROGRAMS
TEAM
Group Leader
María Jesús Cruz Carmona
Principal Investigator (PI)
Miriam Barrechenguren Fernández, Cristina Berastegui Garcia, Susana Gómez Ollés, Marc Miravitlles Fernández, Xavier Muñoz Gall, Iñigo Ojanguren Arranz, Eva Polverino, Berta Sáez Giménez, Ana Villar Gómez, Julia Sampol Sirvent
Researchers
Antonio Álvarez Fernández, Manuel López Meseguer, Víctor Monforte Torres, David Clofent Alarcón, Mario Culebras Amigo, María Luiza De Souza Galvao, Mª José Jurado Luque, Roser Cambrodi, Karina Loor Reyes, Sergi Martí Beltran, Mercedes Pallero Castillo, Mª Antonia Ramón Belmonte, Christian Romero Mesones, Odile Romero Santo-Tomas, David Espejo Castellanos, David Soler Segovia, Galo Granados, Almudena Felipe Montiel, Letizia Traversi, Eva Revilla López, Carlos Bravo Masgoret Jaume Ferrer
PhD Students
Cristina Aljama Vizcarra, Ander Goitisolo Oyon, Victor Guerra Ruíz, Marc Massa Gómez, Gerard Orriols Torras, Mª Florencia Pilia, María Sáez, Sara Salvador Fernández, Anne López, Vanessa Maroto Nouveau, Marta Andreu Casas, Antia Ferreiro Posse, Iván Martínez Ballestero
Lab Technicians
Ares de Moner Ferran, Janet Illa, Carla Niño, María Acevedo, Sonia López Rodríguez, Rosa Lloria Verges, Montserrat Murillo Andrés, Jordi Rabadán Carnicero, Marcela Salazar.
SELECTED PUBLICATIONS
Soler-Segovia D, Romero-Mesones C, Espejo D, Pilia F, Ojanguren I, Martinez-Rivera C, Muñoz X, Cruz MJ
Effects of Pollution: Comparison Between Patients With Asthma and Healthy Individuals.
J Investig Allergol Clin Immunol 2025:0
DOI: 10.18176/jiaci.1094
IF: 4.8
Pollock J, Polverino E, Dhar R, Dimakou K, Traversi L, Bossios A, Haworth C, Loebinger MR, De Soyza A, Vendrell M, Burgel PR, Mertsch P, McDonnell MJ, Skgrat S, Maiz-Carro L, Sibila O, van der Eerden M, Kauppi P, Hill AT, Wilson R, Milenkovic B, Menéndez R, Murris M, Crichton ML, Borecki S, Obradovic D, Irfan M, Eshenkulova V, Nowinski A, Amorim A, Torres A, Lorent N, Welte T, Blasi F, Van Braeckel E, Altenburg J, Shteinberg M, Boersma W, Elborn JS, Aliberti S, Ringshausen FC, Goeminne P, Chalmers JD
Use of inhaled corticosteroids in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)
Thorax 2025;80(6):358-368
DOI: 10.1136/thorax-2024-221825
IF: 7.7
Rodríguez-Chiaradía DA, Torres-Castro R, Piccari L, García-Ortega A, Perez-Peñate GM, de Miguel-Díez J, Perez-Rojo R, Cano-Pumarega I, Mora-Cuesta V, Blanco I, Figueira-Gonçalves JM, Del Pozo R, López-Meseguer M, Martínez-Meñaca A, Tenes A, Molina-Molina M, Barberà JA
A Systematic Review and Expert Recommendation on the Diagnosis of Pulmonary Hypertension Associated With Lung Disease: A Position Paper of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR).
Arch Bronconeumol 2025;61(10):617-625.
DOI: 10.1016/j.arbres.2025.03.015
IF: 9.2
Jeebhay MF, Suojalehto H, Tarlo SM, Suarthana E, Cullinan P, Lindström I, Mason P, Munoz X, Raulf M, Valverde M, Walusiak-Skorupa J, Henneberger P.
A Novel Questionnaire and Algorithm for Work-Related Asthma Screening and Surveillance: An EAACI Task Force Report.
Allergy 2025;80(12):3260-3273.
DOI: 10.1111/all.16647
IF: 12
SELECTED PROJECTS
Environmental stressors as causal determinants for immune-mediated diseases – mapping and prioritising evidence for knowledge-based policy-making (EXPOSIM)
Principal Investigator: PI: María Jesús Cruz / CoPI: Xavier Muñoz
Agency: European Commission
Funding: 515,000 €
Period: 2025 - 2029
Efectos de la exposición a microplásticos en individuos asmáticos: respuesta inmunológica y mecanismos inflamatorios.
Principal Investigator: Xavier Muñoz Gall
Agency: Instituto de Salud Carlos III (PI24/00762).
Funding: 121,250 €
Period: 2025 - 2027
Identificación de endotipos con valor pronóstico en la enfermedad pulmonar asociada al DAAT y en la EPOC
Principal Investigator: Miriam Barrecheguren
Agency: Instituto de Salud Carlos III (PI24/00649).
Funding: 127,500 €
Period: 2025 - 2027
Development of ORK-2 a potent and selective first-in-class drug for the treatment of severe asthma.
Principal Investigator: María Jesús Cruz Carmona
Agency: PROYECTOS DE COLABORACIÓN PÚBLICO PRIVADA CALL 2024 (Ministerio de Ciencia, Innovación y Universidades).
Funding: 412,239 €
Period: 2025 - 2028
Mapping Exposure-Induced Immune Effects: Connecting the Exposome and the Immunome (EXIMIOUS)
Principal Investigator: PI: María Jesús Cruz carmona / CoPI: Xavier Muñoz Gall
Agency: European Commission (EXIMIOUS_H2020_SC1-BHC-2019)
Funding: 395,500 €
Period: 2020 - 2025
PATENTS
DISSEMINATION ACTIVITIES
BCNspiracy
Place: CosmoCaixa
Date: 15/11/2025
Brief: María Jesús Cruz Carmona participated in the conference: Health and the Environment: An Inseparable Relationship.
World Environment Day
Place: VHIR
Date: 05/06/2025
Brief: Indoor Pollution. Communication action for patients and staff at Vall d’Hebron Hospital Participants: Hospital and VHIR Environmental Commission (among the members: María Jesús Cruz, Xavier Muñoz).
European Researchers’ Night 2025: Research Mornings
Place: Escola Estel (Barcelona)
Date: 03/10/2025
Brief: Research Mornings. María Jesús Cruz Carmona. Activity about pollution with the class room
International Day of Women and Girls in Science
Place: VHIR
Date: 11/02/2025
Brief: Scope: 5th and 6th grade primary school students
Speaker: Susana Gómez Ollés
Youth for Medicine. Fundació Catalunya La Pedrera
Place: La Pedrera
Date: during 2025
Brief: Scope: High school students with an interest in medical careers
Participants: Several members of the group
